A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects

Exclusion Criteria

• •Pregnant (positive pregnancy test) or lactating women.
• •Co-infection with other viruses such as Hepatitis A Virus (HAV), Hepatitis C Virus (HCV), Hepatitis D Virus (HDV), Hepatitis E Virus (HEV), Human Immunodeficiency Virus (HIV), Syphilis, etc.;
• •History of cirrhosis or evidence of significant fibrosis or cirrhosis before or during screening;
• •History of hepatocellular carcinoma (HCC) or suspected HCC before or during screening.;
• •History of malignant tumors within the past 5 years prior to screening, except for certain cancers that can be completely cured by surgical resection;
• •Subjects with other chronic liver diseases, including but not limited to autoimmune liver disease, alcoholic liver disease, Wilson's disease, Gilbert syndrome, etc;
• •Previous organ or bone marrow transplantation;
• •Clinically significant abnormal laboratory test results at screening.
• •Poorly controlled thyroid diseases or clinically significant thyroid dysfunction;
• •Autoimmune diseases;
• •Significant systemic or major illnesses other than liver disease.
• •Any systemic anti-tumor or immunosuppressive therapy, or immunomodulatory therapy within 6 months prior to screening.
• •High-dose systemic corticosteroids use within 3 months prior to screening;
• •History of alcohol or drug abuse within the past year or excessive alcohol consumption.
• •History of blood transfusion within 2 months prior to screening;
• •History of allergy to investigational drug or its excipients.
• •Previously participated in the clinical trial of hepatitis B core protein allosteric modulators;
• •Participation in another clinical trial and receipt of an investigational drug within the following timeframes before the first dose in this study: 5 half-lives (if known) or twice the duration of the biological effect of the study treatment (if known), whichever is longer, or 90 days (if the half-life or duration is unknown);
• •History or condition of cardiovascular disease;
• •Any other condition deemed inappropriate for inclusion by the investigator.